Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
0.8938
+0.0394 (+4.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invivyd, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 04, 2025
Via
Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
↗
February 04, 2025
Via
Benzinga
Top movers in Monday's session
↗
February 03, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
Discover the most active stocks in Monday's session.
↗
February 03, 2025
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via
Chartmill
Earnings Outlook For Invivyd
↗
November 13, 2024
Via
Benzinga
Keep an eye on the top gainers and losers in Monday's session.
↗
February 03, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
↗
February 03, 2025
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
↗
February 03, 2025
Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.
Via
Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
↗
February 03, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
February 03, 2025
Via
Benzinga
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Which stocks are moving after the closing bell on Friday?
↗
January 31, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
January 27, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
January 27, 2025
From
Invivyd
Via
GlobeNewswire
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
↗
January 10, 2025
Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 10, 2025
Via
Benzinga
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
January 10, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 14, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
November 12, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
November 06, 2024
From
Invivyd
Via
GlobeNewswire
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
November 06, 2024
From
Invivyd
Via
GlobeNewswire
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
October 30, 2024
Via
Benzinga
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
October 29, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
October 29, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
October 16, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
October 01, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
September 23, 2024
From
Invivyd
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
